-+ 0.00%
-+ 0.00%
-+ 0.00%

Recursion Reaches FDA Alignment on Phase 3 Trial Design for REC-4881 in FAP

PUBT·11/18/2026 09:59:38
Listen to the news
Recursion Reaches FDA Alignment on Phase 3 Trial Design for REC-4881 in FAP
  • Recursion secured FDA alignment on a registrational Phase 3 trial design for REC-4881, an investigational oral treatment for familial adenomatous polyposis.
  • The trial is scheduled to begin in the second half of 2027, enrolling approximately 200 adults following colectomy or proctocolectomy.
  • The primary endpoint will count removal of adenomas measuring at least 10 mm anywhere in the gastrointestinal tract as an event.
  • Previously reported Phase 2 TUPELO results showed substantial, rapid reductions in polyp burden, including larger, higher-risk polyps.
  • The disease has no approved pharmacologic therapies, creating a potential first-in-class opportunity for REC-4881.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180459PRIMZONEFULLFEED9880279) on November 18, 2026, and is solely responsible for the information contained therein.